U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarter ended:   March 31, 2001

Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

          New York                                         65-0565144
-------------------------------                        -------------------
(State or other jurisdiction of                         (I.R.S. Employer
incorporation or organization)                          Identification No.)

         2018 Oak Terrace
        Sarasota, Florida                                    34231
---------------------------------------                   ----------
(Address of principal executive offices)                  (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:

                                                  Name of each exchange on
      Title of each class                         which registered

               None
-----------------------------                     -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)


Copies of Communications Sent to:

                                 Mercedes Travis, Esq.
                                 Mintmire & Associates
                                 265 Sunrise Avenue, Suite 204
                                 Palm Beach, FL 33480
                                 Tel: (561) 832-5696; Fax: (561) 659-5371



<PAGE>


     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                   Yes     X        No
                            ---            ---

     As of March 31, 2001,  there are  14,163,346  shares of voting stock of the
registrant issued and outstanding, all of which have voting rights..














<PAGE>



PART I

Item 1.            Financial Statements


Condensed Consolidated Balance Sheets                            F-1

Condensed Consolidated Statements of Operations                  F-2

Condensed Consolidated Statements of Cash Flows                  F-3

Notes to the Financial Statements                                F-5















<PAGE>



<TABLE>
<CAPTION>
                  SURGICAL SAFETY PRODUCTS, INC. AND SUBSIDIARY

                      CONDENSED CONSOLIDATED BALANCE SHEETS



                                                           March 31,                December 31,
                                                              2001                      2000
                                                        ----------------         -------------------

                  Assets
<S>                                                   <C>                       <C>
Current Assets
  Cash and cash equivalents                           $                -        $             52,247
  Trade receivables                                               25,243                       8,022
  Employee advances                                                1,500                       1,500
  Certificates of deposit                                              -                      50,000
  Prepaid expenses                                                 9,039                      26,409
  Assets held for sale                                            29,372                      27,600
                                                        ----------------         -------------------
    Total current assets                                          65,154                     165,778

Property and equipment, net                                            -                      71,973
                                                        ----------------         -------------------

Other Assets
  Deferred loan costs, net                                             -                           -
  Intangible assets, net                                          43,384                      44,278
  Software development costs, net                                 25,240                      26,629
  Investments                                                      9,750                       9,750
  Deposits                                                        33,395                       4,645
                                                        ----------------         -------------------
    Total other assets                                           111,769                      85,302
                                                        ----------------         -------------------







Total Assets                                          $          176,923        $            323,053
                                                        ================         ===================
</TABLE>





<PAGE>






<TABLE>
<CAPTION>
                                                               March 31,                December 31,
                                                                    2001                        2000
                                                         ---------------         -------------------
<S>                                                   <C>                       <C>
Liabilities and Stockholders' Equity

Current Liabilities
  Bank overdraft                                       $           5,210        $                  -
  Line of credit                                                  45,945                     100,000
  Accounts payable                                               127,986                      90,666
  Accrued payroll                                                103,126                      94,251
  Accrued legal                                                  264,015                     264,015
  Deferred revenue                                               104,239                     177,875
  Accrued interest - related parties                               3,506                       2,629
  Notes payable - bridge loan                                     81,000                           -
  Notes payable - related parties                                 35,063                      35,063
                                                         ---------------         -------------------
    Total current liabilities                                    770,090                     764,499

Long-Term Liabilities
   Note payable                                                  607,451                     842,795
                                                         ---------------         -------------------
    Total Liabilities                                          1,377,541                   1,607,294
                                                         ---------------         -------------------


Stockholders' Equity(Deficit)

Common stock, $.001 par value,   20,000,000 shares
authorized; 14,163,346 and 14,865,373 shares issued
and outstanding in 2001 and 2000 respectively                     14,163                      14,866
  Common stock held in escrow                                          -                      (1,365)
  Additional paid-in capital                                   4,089,306                   3,841,398
  Accumulated deficit                                         (5,304,087)                 (5,139,140)
                                                         ---------------         -------------------
    Total stockholders' equity (deficit)                      (1,200,618)                 (1,284,241)
                                                         ---------------         -------------------

Total Liabilities and Stockholders' Equity             $         176,923        $            323,053
                                                         ===============         ===================
</TABLE>



   The accompanying notes are an integral part of these financial statements.
                                       F-1



<PAGE>




<TABLE>
<CAPTION>
                  SURGICAL SAFETY PRODUCTS, INC. AND SUBSIDIARY

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                   THREE MONTHS ENDED MARCH 31, 2001 AND 2000

                                                               2001                     2000
                                                         ----------------         -----------------
<S>                                                     <C>                     <C>
Revenue                                                 $         111,359       $           135,656

Costs and expenses
  Cost of medical products sold
                                                                   14,532                       108
  Operating expenses                                              177,296                   376,633
  Research and development expenses                                     -                    14,345
  Interest expense                                                 14,102                   181,421
  Loss on disposal/impairment of assets                            70,376                         -
                                                         ----------------         -----------------
    Total costs                                                   276,306                   572,507
                                                         ----------------         -----------------

Net loss before income taxes                                     (164,947)                 (436,851)

Provision for income taxes                                              -                         -
                                                         ----------------         -----------------

Net loss                                                $        (164,947)       $         (436,851)
                                                         ================         =================

Net loss per share                                      $         (0.012)       $           (0.038)
                                                         ================         =================
</TABLE>










   The accompanying notes are an integral part of these financial statements.
                                       F-2



<PAGE>




<TABLE>
<CAPTION>
                  SURGICAL SAFETY PRODUCTS, INC. AND SUBSIDIARY

                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                   THREE MONTHS ENDED MARCH 31, 2001 AND 2000

                                                                                        2001                     2000
                                                                            ----------------         ----------------
<S>                                                                        <C>                     <C>
Cash Flows From Operating Activities
  Net loss                                                                 $        (164,947)      $         (436,851)
                                                                            ----------------         ----------------
  Adjustments to reconcile net loss to cash used in
operating activities
      Depreciation and amortization                                                    1,991                   43,357
      Common stock issued for services                                                     -                   24,280
      Accrued interest added to notes payable                                         14,286
      Interest expense - issuance of convertible debt                                      -                  167,140
      Loss on disposal/impairment of assets                                           70,376
      Decrease (increase) in operating assets
        Receivables                                                                  (17,221)                (129,468)
        Prepaid expenses and deposits                                                (11,380)                  10,980
      Increase (decrease) in operating liabilities
        Accounts payable and accrued expenses                                         47,074                 (190,751)
        Deferred revenue                                                             (73,636)
                                                                            ----------------         ----------------
          Total adjustments                                                           31,490                  (74,462)
                                                                            ----------------         ----------------
            Net cash used in operating activities                                   (133,457)                (511,313)
                                                                            ----------------         ----------------

Cash Flows From Investing Activities
  Proceeds from bridge loan                                                           81,000                        -
  Software development additions                                                           -                  (15,618)
  Furniture and equipment purchased                                                        -                   (3,056)
                                                                            ----------------         ----------------
    Net cash provided by (used in) investing activities                               81,000                  (18,674)
                                                                            ----------------         ----------------

Cash Flows From Financing Activities
  Payments on line of credit, net                                                     (5,000)                       -
  Financing and loan costs                                                                 -                  (70,000)
  Proceeds from long-term debt                                                             -                  650,000
                                                                            ----------------         ----------------
    Net cash provided by (used in) financing activities                               (5,000)                 580,000
                                                                            ----------------         ----------------

Net increase (decrease) in cash                                                      (57,457)                  50,013
Cash and cash equivalents at beginning of year                                        52,247                  516,799
                                                                            ----------------         ----------------
Cash and cash equivalents at end of year                                   $          (5,210)      $          566,812
                                                                            ================         ================
</TABLE>





<PAGE>







<TABLE>
<S>                                                                   <C>                    <C>
                                                                                 2001                    2000
                                                                       --------------         ---------------
Supplemental Cash Flow Information:
  Cash paid for interest                                              $             -        $              -
                                                                       ==============         ===============
</TABLE>

For purposes of the statement of cash flows,  management  considers all deposits
and financial  instruments with original maturities of less than three months to
be cash and cash equivalents.


Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:

Three Months Ended
March 31, 2001

-    Certificate of deposits pledged against the line of credit were used to pay
     down the line of credit in the amount of $50,000.
-    Common  stock and  additional  paid in capital of  $248,570  issued for the
     conversion of notes payable.
-    Equipment with a value of $1,772 transferred to assets held for sale.


Three Months Ended
March 31, 2000

-    Common stock issued for $52,273 of prepaid investment services.
-    Deferred financing costs of $231,385 related to the issuance of warrants in
     conjunction with issuance of notes payable.







   The accompanying notes are an integral part of these financial statements.
                                       F-3



<PAGE>



Note 1 - Accounting Policies
Basis of Presentation
The  condensed  financial  statements  of Surgical  Safety  Products,  Inc.  and
Subsidiary (Company) have been prepared without audit, pursuant to the rules and
regulations of the Securities and Exchange  omission.  Certain  information  and
footnote  disclosures  normally  included in  financial  statements  prepared in
accordance wit generally accepted  accounting  principles have been condensed or
omitted pursuant to such rules and  regulations.  These  consolidated  financial
statements  should be read in  conjunctions  with the financial  statements  and
notes  thereto  included in the  Company's  Annual Report on Form 10-KSB for the
year ended December 31, 2000.

The results of  operations  for the three month  period ended March 31, 2001 are
not necessarily indicative of the results to be expected for any other period or
for the full year.

In the opinion of Company's  management,  the accompanying  unaudited  financial
statements  contain  all  adjustments,  consisting  of only  normally  recurring
adjustments,  necessary to present  fairly the financial  positions of March 31,
2001,  the results of operations and cash flows for the three months ended March
31, 2001 and March 31, 2000.

Reclassifications
Certain   reclassifications  have  been  made  in  the  prior  year's  financial
statements to conform to the current period presentation.

Net Loss Per Share
Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) No. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents have not been included in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.



Note 2 - Assets Held for Sale
During the first  quarter  of fiscal  2001,  the  Company  transferred  computer
equipment  with a fair market  value of $1,772 from  Property  and  Equipment to
Assets Held for Sale. This transfer was completed after management's examination
of all assets and their book values.


Note 3 - Impairments
During the first quarter of fiscal 2001, the Company's  management  examined the
book  value  all  of  the  assets  held  by  the  Company.  As a  result  of the
examination,  all  property  and  equipment  not held for sale was written  off.
Accordingly, the Company recorded and impairment loss of $70,376 as of March 31,
2001.


                                       F-4



<PAGE>




Note 4 - Long Term Debt
On February 7, 2001,  the  investment  banking  firm which held the  outstanding
notes  payable as of December 31,  2000,  converted  $230,000 of  principal  and
$18,570 of accrued interest to 662,854 shares of the Company's common stock at a
conversion price of $0.375 per share. This reduced long-term debt by $248,570.


Note 5 - Subsequent Event
On February  7, 2001 the Company  executed a loan  cancellation  and  settlement
agreement  effectively ending the  line-of-credit  agreement with the investment
banking firm which held the notes  payable as of December 31, 2001.  Pursuant to
the agreement,  on April 3, 2001the lender  converted an additional  $243,665 of
principal  and $19,601 of accrued  interest to 702,043  shares of the  Company's
common  stock at a  conversion  price of  $0.375.  As of the March 31,  2001 the
principal  balance of the amount owed to the lender was  $560,000,  plus accrued
interest of $247,451.  Until fully converted,  the remaining balance will accrue
interest at 8%. In accordance  with the agreement the lender has turned over all
escrowed shares and has committed to convert the remaining principal and accrued
interest as soon as possible.







                                       F-5



<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

     The Company's (OTC BB: SURG) overall mission is the research,  development,
production and distribution of innovative  products and services for healthcare.
Consisting  of both  traditional  products and  innovative  business-to-business
e-solutions,  the  common  goal is a safer and more  efficient  environment  for
healthcare workers,  manufacturers and patients.  Originally formed as a medical
device company,  Surgical shifted focus to being an e-company when the Company's
management recognized an untapped market niche:  responding to the critical need
for immediate communication and access to information in healthcare.

     Now, the Company operates two divisions  providing products and services to
the medical industry. The Information Systems Division,  formerly referred to as
Oasis@work,  through  its  Oasis  Information  Exchange  product  line  provides
business-to-business  on-demand  safety and  efficiency  driven  e-business  and
information for healthcare  workers.  The Medical Products and Services Division
develops, manufactures and distributes medical devices.

About Oasis Information Exchange

     The Oasis  Information  Exchange ("OIX") strategy is healthcare  e-business
content  aggregation  and  applications  integration  through a virtual  private
network.  It links the entire healthcare  continuum,  which includes  healthcare
workers,   administration,   patients,   and   healthcare   and   pharmaceutical
manufacturers.  Oasis Information Exchange is a true healthcare data center with
multiple  access  points.  It  is  an  Internet-based  virtual  private  network
consisting of points-of-access via intranets, the Internet, internet appliances,
and through  TouchPorts  located  throughout  healthcare  facilities  across the
country.  Although the Company is now focusing on providing its services through
the  Internet,   TouchPorts   remain   available  as  an  alternative   and  are
user-friendly   touch-access   internet   appliances   which  allow   healthcare
professionals  access to high quality  clinical  reference  and agency  mandated
information services.

     OIX consists of three lines of e-business.  The primary product produced by
OIX is a service that creates customized training applications for virtually any
topic. These web browser-based  educational  modules are designed to provide the
end-user with succinct,  current information on any topic within practically any
industry.  As a second  line of  business,  OIX builds  on-line  communities  in
specific target markets positioned as information  exchanges.  The third line of
business,  a  natural  by-product  of the first  two,  is  Internet  application
development and support services

     During  the third  quarter of 2000,  the  Company  realized  that they were
focusing too much attention to the installation of hardware rather than focusing
its  attention  on its real  product -  information.  In July 2000,  the Company
signed an agreement with the  Association  of  periOperative  Registered  Nurses
("AORN"),  one of the largest  nursing  organizations  in the United States,  to
license their content - AORN Journal  Online,  OR Product  Directory,  Standards
Recommended  Practices and Guidelines  (SRPG) and other content.  See "Corporate
Developments".



<PAGE>



     AORN has 43,000 members and other mailing lists comprising of an additional
100,000 people. As part of this initiative,  the Company was to produce a CD-ROM
for mailing in January 2001.  This CD featured  OASiS.  The CD was mailed in the
AORN Journal for members.

     Due to the increase and availability of PC's and Internet  accessibility in
the heathcare  environment,  the Company  realizes that, while in some cases its
OASiS  network is needed in a particular  environment,  by an large,  its larger
market is for its content.  Essentially  the Company is changing from a hardware
network  supplier to an  information  broker  which will  create an  information
exchange network for a defined healthcare  community that links the end-users to
the industry while adding value to both parties.  This is  essentially  what the
Company was doing all along;  however, it had focused on the delivery system for
its product rather than the product itself.

     Under the AORN arrangement, the Company's product will be delivered through
the  Internet  via its  website  or  information  exchange  which will be called
OasisOR.com.  The data  center  will have the same type of content  from  device
manufacturers,  clinical  associations and other relevant resources;  however it
will be for OR employees only, with the information  relevant to them.  Although
AORN has ended the original agreement, negotiations are on-going to re-establish
a joint working  relationship.  The Company has created a digital version of the
AORN's Operating Room Product  Directory and continues to host content on behalf
of AORN.

     Although  the Company  pays AORN  licensing  fees,  the Company  expects to
generate revenue from  sponsorships of the CD and from user fees and advertising
on its website.  The Company negotiated its first sponsorship  agreement with US
Surgical in lieu of the previous  agreement which required massive  expenditures
for hardware  installations.  A number of additional corporate content providers
also have been added as clients, including Stryker, Storz, Haemacure and others.

     The Company  plans to scale the concept for other niche markets by creating
websites  that  cater to a  particular  speciality.  The  Company  will focus on
providing website and intranet development.

     SutureMate(R)

     SutureMate(R),  a  patented,   disposable,   surgical  assist  device,  was
initially   introduced  in  1993.  Its  unique  design  facilitates  the  highly
recommended  one-handed  suturing  technique  which is advocated by occupational
safety experts.  When one-handed  suturing is not used, extra steps are required
by the surgeon or the  assistant in cutting the needle free of the suture thread
and extra time and hand  movements  are  required  of the  surgeon  in  manually
adjusting  needles  while  using a needle  holder  in most  suturing  processes.
SutureMate(R)  allows  the  surgeon  to use a safer,  more  efficient  method of
surgical   stitching.   The  product   has   features   which   include  a  foam
needle-cushion, and a suture cutting slot.

     SutureMate(R)  was re-designed in late 1998 and has been re-released  since
demand has increased due to statutory changes relating to needlestick  injuries.
Legislation has been adopted at both the federal and state level. An overview of
state needle safety legislation can be viewed at www.cdc.gov/niosh/ndl-law.html.
This legislation essentially requires state agencies with


<PAGE>



employees at rist to  implement  needleless  systems and sharps with  engineered
sharps injury  protection in order to prevent the spread of bloodborn  pathogens
in the workplace.

     The product was  re-engineered  and updated after  feedback from over 4,000
surgeons and surgical  technologists  who used or reviewed the product since its
inception.  As a result of the re- design,  the Company  believes that there are
new clinical  advantages and that the product can be produced at a significantly
lower manufacturing cost. These beliefs are based on the fact that the re-design
includes  a  tent-like  configuration  with a hidden  cutting  device  contained
between the  adhesive  base and the holding  device.  This allows the surgeon to
separate  the needle from the suture  without a scrub nurse  intervening  with a
scissor.  The cost reduction will result from the fact that the original version
cost  approximately  $6.00 per unit while the new  version  costs  approximately
$1.10 per unit including packaging and sterilization, allowing it to be marketed
in the $5 to $6 range which is more in keeping  with  pricing  for a  disposable
product.  Due to its proven history,  SutureMate(R)  is a "proven"  product that
complies with current legislation.

     On  Feb  13,  2001,  the  Company   announced  an  agreement  with  DeRoyal
Industries,  Inc. ("DeRoyal")to distribute  SutureMate(R) worldwide.  DeRoyal is
the largest  privately held healthcare  supplier of safety devices with over 250
sales  representatives  worldwide.  Formed in 1973,  DeRoyal is a international,
vertically-integrated supplier of institutional and consumer healthcare products
and services,  with 27 subsidiaries and affiliates in seven states  (California,
Florida,  Georgia,  Oklahoma,  South Carolina,  Tennessee, and Virginia) and ten
countries (Canada, Costa Rica, England,  Estonia,  Germany,  Ireland, Italy, the
Netherlands, Sweden and the United States). DeRoyal's four business units, Acute
Care, Patient Care, Wound Care and OEM (original equipment manufacturer) produce
more than 25,000  products,  including:  rehabilitation  and  therapy  products,
sports  medicine  supports,  orthopedic  bracing and  supports,  fiberglass  and
plaster  casting;  wound care dressings;  unitized  surgical  delivery  systems,
including TracePak and custom procedural trays; surgical accessories;  neonatal,
labor  and  delivery   products;   angiographic,   endoscopic,   anesthesia  and
temperature  monitoring products; as well as manufacturing services in plastics,
textiles,  electrical  manufacturing,   converting  and  sterilization.  DeRoyal
introduced the re-designated SutureMate(R) at AORN in March, placed an order for
8,000 units for which the Company was paid when it made delivery in May 2001.

     Currently,  the  re-designed  SutureMate(R)  is  manufactured by the Hansen
Plastic  Division of Tuthill  Corporation  at their plant located in Clearwater,
Florida  ("Tuthill").  The Company is in the process of  negotiating  additional
manufacturing sources and original equipment manufacturer sales.

Corporate Developments

     The Company  entered into an agreement with IBM Global  Services  effective
January 3, 2000 which included an IBM Customer Agreement and a Statement of Work
(the "IBM Global  Agreement").  Under the terms of the IBM Global  Agreement IBM
agreed to provide  complete  implementation  and support  service  solutions for
1,200 OASiS terminals in an estimated 400 end user locations during the 12 month
period commencing December 1, 1999. On February 3, 2000, IBM Global Services and
the Company  finalized the Statement of Work.  The services to be provided under
the agreement  included project  planning,  site surveys,  product  acquisition,
network design, web-site hosting services, premises wiring, OASiS TouchPort


<PAGE>



Implementation,  help desk support and consulting  services.  The estimated cost
for erforming the work was  approximately $10 million.  In addition,  IBM Global
Services  agreed to bill the Company a monthly  service  charge for pre and post
installation support services, including 24-7 support, and for labor, travel and
out of pocket  expenses.  The Company  was to provide  technical  resources  and
oversee the IBM Global's activities.  Due to the new Internet focus, the Company
has chosen to pursue for the  delivery  of its  product,  there is no longer any
need for the  services to be  provided by IBM.  Effective  July 14,  2000,  this
contract was  terminated.  In March 2001,  IBM brought suit against the Company.
See Part II, Item 1. "Legal Proceedings."

     Effective June 7, 2000, the Company's line of credit with SouthTrust in the
amount of $100,000 was renewed through August 12, 2000, with an option to extend
the maturity  until  October 15, 2000 if the Company  pledged a  certificate  of
deposit in the amount of $25,000.  The interest  rate is prime plus 1.5% and the
line is secured by the Company's equipment,  receivables and inventory. The line
is guaranteed  personally by Dr. Swor. The line of credit was renewed on October
15, 2000 and the maturity date is December 31, 2000. The outstanding  balance at
such time was $100,000. The Company pledged an additional $25,000 certificate of
deposit to secure the line. As of December 31, 2000, the outstanding balance was
$100,000. In January 2001, the Company paid down the line of credit with the two
(2)  pledged  certificates  of  deposit.  As of this date a balance  of  $50,945
remains outstanding and the Company is in default on the terms of the agreement.

     Effective  July 1, 2000,  the Company  entered into an agreement  with AORN
under  which  AORN  will  provide  certain  of  its  proprietary  content  on  a
non-exclusive  license  basis to the  Company.  Under the  agreement,  AORN will
deliver to the Company  certain of its content for which it grants the Company a
non-exclusive  license to market and promote. The Company receives a substantial
credit toward advertising in the AORN Journal and other AORN  publications.  The
Company is required to provide the  software  and hardware to promote and market
the AORN  content.  The Company is required to pay AORN  $117,000 as the license
fee and contact  hours fee for the first year of the  agreement.  The Company is
required to pay one-half of the license fee by December 15, 2000.  To date,  the
Company has made payments  related to the license fee in the amount of $25,0000.
AORN will reimburse the Company for certain conversion costs and to pay the cost
of web enabling  Home Study  Courses  sponsored by AORN.  The agreement is for a
term of three  (3)  years and it may be  terminated  by either  party on 180 day
notice. If terminated  without cause, the Company is entitled to a refund of any
unused  license  and user  fees.  AORN  retains  ownership  of its  intellectual
property  while the Company  retains  the  ownership  of its OASiS  intellectual
property.  As of December 31, 2000, the Company still owes AORN $33,000  related
to the first  payment of  $58,500  that was paid as of  December  15,  2000.  In
January  2001,  AORN gave the  Company  notice  of  termination.  The  agreement
requires 180 days notice and provides for refund,  but the Company  continues to
negotiate  with  AORN on this and  further  business  such as on- line  products
directories.


     In  December  1999,  the Company  executed a Loan  Agreement  with  Thomson
Kernaghan & Co.,  Ltd.  ("TK"),  as Agent and Lender,  whereby TK agreed to make
loans to the Company of up to $5,000,000 in installments for a period commencing
with the date of the  agreement  and ending on  November  30, 2002 (the "TK Loan
Commitment"). The Company may request


<PAGE>



     additional  draws of no less than  $500,000  provided  its Common Stock has
traded for a minimum of $1.00 for 20  consecutive  days and the stock has had an
average  trading  volume  of  25,000  shares  for the  same  period.  Due to the
Company's  current share price, it does not qualify for additional draws at this
time. Under the terms of the TK Loan  Commitment,  each installment is supported
by a  convertible  note and  security  agreement  and the Agent and  Lender  are
granted  warrants to purchase  shares of the Company's  Common  Stock.  Further,
2,700,000 shares are held by TK in escrow for the potential conversion under the
notes or exercise of the warrants.  Under the terms of the TK Loan Agreement, an
initial loan of $650,000  was made on December  30, 1999.  On March 31, 2000 the
Company received a second  installment  under the TK Commitment in the amount of
$650,000.  On April 28,  2000,  TK elected to convert  $100,000  of  outstanding
principal  and $2,630 of the accrued  interest  into shares of Common Stock at a
price of $0.5625 per share which represents  182,453 shares. On June 9, 2000, TK
elected to convert  $120,000 of outstanding  principal and $4,129 of the accrued
interest  into  shares of  Common  Stock at a price of  $0.375  per share  which
represents  331,010  shares.  On July 11, 2000, TK elected to convert $40,000 of
outstanding  principal  and  $1,683.13  of the accrued  interest  into shares of
Common Stock at a price of $0.375 per share which represents  111,155 shares. On
October 24, 2000, TK elected to convert  $250,000 of  outstanding  principal and
$16,219 of the accrued interest into shares of Common Stock at a price of $0.375
per share which represents  709,918 shares.  The Company granted TK registration
rights  and was  obligated  to file a Form S-3  within  sixty  (60)  days of the
agreement.  The Company filed a  registration  statement on Form S-3 on March 2,
2000 covering  initially  20,038,097 shares of its Common Stock. The issuance of
the  securities  was made  pursuant  to  Regulation  S of the Act.  The Form S-3
registration  statement  was declared  effective  on April 11,  2000.  Since the
Company did not meet  financial  projections  which were an integral part of the
transaction,  TK and the Company  re-negotiated the arrangement which terminated
the Loan Commitment and settled all matters between the parties.

     Pursuant to a loan cancellation and settlement agreement effective February
7, 2001 (the "Cancellation Agreement"),  TK agreed to convert the balance of the
December 1999 debt in the amount of $140,000 plus accrued and unpaid interest in
the amount of $12,395 and to convert $90,000 on the  installment  given on March
31, 2000 under the Loan  Commitment  plus accrued and unpaid  interest of $6,175
into a total of 662,854  shares of the Common Stock  registered  by the Form S-3
registration,  thereby leaving an outstanding  principal balance dating to March
31, 2000 of $560,000  plus accrued and unpaid  interest  (the "March  Balance").
Interest  on the March  Balance  shall  continue  to accrue at the rate of eight
percent (8%) per annum;  however, all future interest payments, at the option of
the  Company,  may be made in cash or by  delivery  of  registered  shares  at a
conversion  price  equal per share  equal to the  amount of  accrued  and unpaid
interest as of the  conversion  or  repayment  date  divided by the five (5) day
average closing bid price prior to the conversion or repayment date. Further, TK
committed,  subject to not exceeding  ownership of 4.99%,  to convert as soon as
possible the March Balance. The Company may continue to repay all or any part of
the March  Balance in cash.  TK agreed to return  all shares  held in escrow and
agreed to a triangular merger contemplated by the Company.  Provided such merger
occurred  before May 15, 2001,  TK agreed not to sell,  directly or  indirectly,
more than twenty-five  percent (25%) of the Company's volume in any trading day.
Such anticipated merger, to be discuss below, did not occur before May 15, 2001.
In consideration of the  Cancellation  Agreement and the accelerated  conversion
into the Company's  shares,  the Company  agreed to issue 682,108  shares of its
restricted  Common  Stock in relation to the balance of the  December  1999 debt
which was converted and


<PAGE>



     3,109,487  shares of its  restricted  Common Stock in relation to the March
31, 2000  installment  as bonus shares (the "Bonus  Shares")  Additionally,  the
Company granted,  for a period of two years,  both the Lender and the Agent each
warrants to purchase 380,000 shares of the Company's  restricted Common Stock at
$0.1846 per share (the "Bonus  Warrants").  Until fully converted,  TK was given
the  option  to place an  independent  third  party  on the  Company's  Board of
Directors.  Of the 20,038,097  shares  registered on Form S-3, only those shares
issued  pursuant to the earlier  conversions  and pursuant to the  agreement and
original  Lender and Agent Warrants would be registered  with the balance deemed
null and void. Accordingly,  the registration of 13,255,946 potentially issuable
registered shares would be null and void and such shares would not be issued .

     Following  execution  of  the  Cancellation   Agreement,  TK  converted  an
additional  $243,665 of  principal  on the March  Balance and accrued and unpaid
interest  in the  amount  of  $19,601  into  a  total  of  702,043  shares.  The
certificate  for shares held in escrow was cancelled and there are no longer any
escrowed shares in relation to the arrangements  between the parties.  As of the
date hereof, the principal  indebtedness to TK is in the amount of $316,335 plus
accrued and unpaid interest from March 31, 2000.

     Until fully converted,  the TK Loan Commitment,  as interest accrues,  will
increase  the long term debt of the Company.  The Company is  currently  seeking
other potential funding. With the TK Loan Commitment and in the event additional
debt is raised,  the Company will incur  future  interest  expense.  The TK Loan
Commitment,  if fully converted and all warrants are exercised,  will dilute the
interest of existing  shareholders and in the event additional equity is raised,
management  may be  required to dilute the  interest  of  existing  shareholders
further or forego a substantial interest in revenues,  if any. In the event that
the Company is successful in securing  additional debt financing,  the amount of
such  financing,  depending upon its terms,  would increase  either the short or
long term debt of the Company or both.

     In December 2000, the Company formed a Florida  corporation,  OIX Inc. as a
wholly owned subsidiary. The Officers and Directors of Surgical serve in similar
capacities with OIX Inc.


     In February 2001, the Company executed a Term Sheet with Emagisoft  whereby
Emagisoft will merge into OIX, Inc. The shareholders of Emagisoft will exchange
their shares for share in Surgical on a 1 for 1 basis. In addition,  Emagisoft's
Preferred  Shares will exchange their preferred  shares in Surgical's  Preferred
Shares on a 1 for 1 basis.  The  reverse  triangular  merger was  expected to be
completed some time in May 2001; however, due to a shortage of funds on the part
of both  Emagisoft  and  Surgical  the merger has not been  completed as of this
date.  Surgical and Emagisoft decided to proceed with merger plans because there
are certain  synergies  that will result from the merged  companies.  Currently,
Surgical  outsources  a great deal of its CD  production  and  computer  design.
Emagisoft  provides such services.  Further,  both companies are within the same
geographic  region and share many of the same suppliers.  Lastly,  Emagisoft has
existing  management  that can provide the stability in management  Surgical has
been seeking over the last few years. As a result of these features,  management
for these two companies  believed that collectively they could achieve the goals
of each of the  companies  at a faster  rate.  Emagisoft  provides  hosting  and
Web-based design solutions for clients in a variety of fields,  from electronics
manufacturing to healthcare


<PAGE>



services.  Their software and technology  offer the high levels of availability,
scalability,  and security  required to ensure the success of  corporate  online
presence.  They are dedicated to exceeding client  expectations with exceptional
Web-based tools and e-commerce services.  It is expected that the combination of
OIX  and  Emagisoft  will  create  exceptional   synergies  for  developing  and
distributing web-based products and services in a variety of healthcare markets.
At the time the merger is  completed,  Surgical  will file on Form 8K a combined
business plan.  Between the date of the execution of the term sheet and the date
hereof, Emagisoft arranged for loans totally approximately $81,000 to be made to
the Company. It is anticipated that these loans will be converted into equity at
the time of the merger.

     On March 16,  2001,  the Company  entered a staff  leasing  agreement  with
Selective HR Solutions ("Selective HR") as a replacement for comparable services
previously  provided  by EPIX.  Like  the EPIX  arrangement,  the  Selective  HR
arrangement  creates a co-employment  relationship  between Selective HR and the
Company relative to the employees who work at the Company

Discussion and Analysis

     The  Company  was  founded  in 1992  to  combat  the  potential  spread  of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

     The  Company  was in  the  development  stage  until  1993  when  it  began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  2000,  the  Company  generated  revenues of
approximately  $1,876,000  from a limited number of customers.  Since  inception
through  December  31,  2000,  the Company has  generated  cumulative  losses of
approximately  $5,140,000.  Although the Company has  experienced  a significant
percentage  growth in revenues from fiscal 1992 to fiscal 2000, the Company does
not believe  prior  growth rates are  indicative  of future  operating  results,
especially in light of the contract with AORN and its new  Internet-based  site,
OASiSOR.com,  and the revised  contract  with US Surgical.  Due to the Company's
operating history and limited  resources,  among other factors,  there can be no
assurance that  profitability  or significant  revenues on a quarterly or annual
basis will occur in the future.  Moreover,  the  Company  expects to continue to
incur operating losses through at least through fiscal 2001, and there can be no
assurance that losses will not continue after such date.

     As discussed in the  independent  auditors'  report,  the operating  losses
incurred  by the  Company  raise  doubt about its ability to continue as a going
concern.  In addition,  with the  implementation of its agreement with AORN, and
its new  arrangement  with US Surgical and/or with the  establishment  of one or
more  strategic  alliances  in  addition  to AORN and US  Surgical,  the Company
expects to  experience a period of growth,  which  requires it to  significantly
increase the scale of its operations.  This will result in significantly  higher
operating expenses. The increase


<PAGE>



     in operating  expenses is expected to be partially funded by an increase in
revenues. However, the Company's net loss may continue to increase. Expansion of
the  Company's  operations  may  cause a  significant  strain  on the  Company's
management,  financial  and other  resources.  The  Company's  ability to manage
recent and any  possible  future  growth,  should it occur,  will  depend upon a
significant  expansion of its sales and  marketing,  research  and  development,
accounting  and other internal  management  systems and the  implementation  and
subsequent improvement of a variety of systems,  procedures and controls.  There
can be no assurance that significant problems in these areas will not occur. Any
failure to expand these areas and implement and improve such systems, procedures
and  controls in an efficient  manner at a pace  consistent  with the  Company's
business  could  have a  material  adverse  effect  on the  Company's  business,
financial  condition  and results of  operations.  As a result of such  expected
expansion and the anticipated increase in its operating expenses, as well as the
difficulty in forecasting  revenue  levels,  the Company  expects to continue to
experience  significant  fluctuations in its revenues,  costs and gross margins,
and therefore its results of operations.

     The Company's  plan of operations for the next twelve months is to focus on
building revenue from production of its web-enabled training applications called
Trainlets that it is currently marketing to healthcare  companies.  In addition,
it  anticipates  additional  revenues  from the  development  of its website and
registered  user  base.  The  Company  also is  aggressively  seeking  strategic
alliances  with targeted  industry  partners such as  manufacturers  of devices,
manufacturers of  pharmaceuticals,  professional  organizations  such as nursing
associations and hospital group purchasing  organizations  and integrated health
networks along the lines created with the AORN contract.

     In  this  regard,   the  Company  executed  a  term  sheet  with  Emagisoft
Technologies  Inc. under which  Emagisoft  will merge into the Company's  wholly
owned subsidiary OIX, Inc. Surgical and Emagisoft decided to proceed with merger
plans because there are certain  synergies  that are expected to result from the
merged  companies.  Currently,  Surgical  outsources  a  great  deal  of  its CD
production and computer design. Emagisoft provides such services.  Further, both
companies  are  within  the same  geographic  region  and share many of the same
suppliers.  Lastly,  Emagisoft  has  existing  management  that can  provide the
stability in management  Surgical has been seeking over the last few years. As a
result of these  features,  management  for these two  companies  believed  that
collectively  they could  achieve the goals of each of the companies at a faster
rate  and  that  the  combined  companies  will be more  attractive  to  outside
financial sources..

     The Company  estimates  that  revenues  will be  sufficient to fund ongoing
operations  at the  current  level  when  the  website  is  functional  and  its
registered  users  base  reach  levels of 50,000 or more.  The  Company  is also
aggressively  marketing its  web-enabled  Trainlets to healthcare  companies for
which it has already received contracts totaling approximately $323,000.

     In the short term, to fund operations through fiscal 2001, the Company will
seek  additional  funds from strategic  alliances with  potential  clients,  its
shareholders,  from additional third party financing or seek third party debt or
equity financing other than those planned by the current


<PAGE>



anticipated  agreements.  As of December 31, 2000,  the Company has utilized its
entire  existing  lines of credit.  As of December 31,  2000,  the Company had a
staff of six (6)  employees.  The  Company  was able to meet its  capital  needs
through year end.

     As discussed in Note 21 to the  Financial  Statements  for the period ended
December  31,2000,  if the  financing  referred  to  above is not  secured,  the
recoverability of the recorded asset amounts may be impaired.

     In 2001,  the Company will require  between $5 and $8 million in additional
capital  in the form of debt or equity to fund the  continued  expansion  of the
Oasis system and its  development to meet increased  demand and to implement its
plans for  increased  marketing of its medical  device  products.  These funding
requirements are based upon the new initiative which is less hardware  intensive
and requires less maintenance.  The Company is in the process of seeking funding
from a number of different sources;  however,  it has accepted no definite offer
at this time.  There can be no assurance that such  long-term  financing will be
available to the Company or that it will be on terms that the Company may seek.

Results of Operations for the Three Months Ended March 31, 2001 and 2000

Overview

     From its inception, the Company has incurred losses from operations.  As of
March 31, 2001,  the Company had cumulative  net losses  totaling  approximately
$5,304,087.  During fiscal 2000,  management  shifted its focus to  aggressively
marketing its  proprietary  products,  especially  those  associated  with Oasis
Information Exchange.

Financial Position

     As of March 31,  2001,  the  Company  had a deficit of  working  capital of
$704,936,  as compared  to a deficit of working  capital of $598,721 at December
31, 2000. This increase in deficit is primarily due to management  examining the
book value of assets and  recording an  impairment  loss,  combined with greater
accounts payable balances and cash deficit.

Revenues

     For the three months  ended March 31, 2001 and 2000,  the Company had total
revenues of $111,359 and $135,656,  respectively.  Revenues for the three months
ended March 31, 2001  consist of sales of  SutureMate  (TM) and  recognition  of
prior  deferred  revenues.  For the three months ended March 31, 2000,  revenues
were  derived  from  payments  received  for Oasis unit  rentals  and  inservice
modules.


<PAGE>




Selling, General, and Administrative Expenses

     For the three months ended March 31, 2001,  operating expenses decreased by
$199,337 or 52% from  $376,633 for the three  months ended March 31, 2000.  This
decrease is primarily related to a down sizing of the Company in anticipation of
the merger with Emagisoft.

     In the past,  the  Company  has  focused on the design and  development  of
proprietary  products.  For fiscal  2000,  the Company  launched  an  aggressive
marketing  plan that is designed to increase  worldwide  sales of its  products.
Surgical  believes that the increased  operating  expenses  incurred  during the
three  months  ended  March 31,  2001 will  position  the  Company  to  generate
increased revenue in the 2001 fiscal year.

Liquidity and Capital Resources

     The financial  condition,  liquidity  and capital  resources of the Company
should be assessed  in context  with the ability of the Company to continue as a
going concern as discussed in the independent auditors' report.

     The  Company's  operations  have been funded  primarily  from bridge  loans
arranged through Emagisoft of approximately $81,000. This allowed the Company to
fund its downsized operations.

     The company has a line of credit with  SouthTrust in the amount of $100,000
that was renewed  through August 12, 2000, with an option to extend the maturity
until October 15, 2000 if the Company  pledged a  certificate  of deposit in the
amount of $25,000.  The interest rate is prime plus 1.5% and the line is secured
by the Company's  equipment,  receivables and inventory.  The line is guaranteed
personally  by Dr. Swor.  The line of credit was renewed on October 15, 2000 and
the maturity date is December 31, 2000. The outstanding balance at such time was
$100,000.  The Company pledged an additional  $25,000  certificate of deposit to
secure the line. As of December 31, 2000, the outstanding  balance was $100,000.
In  January  2001,  the  Company  paid down the line of credit  with the two (2)
pledged  certificates  of deposit.  As of this date a balance of $45,945 remains
outstanding and the Company is in default on the terms of the agreement.

     Net cash used for  investing  for the three months ended March 31, 2001 was
approximately  $81,000,  representing primarily the bridge financing arranged by
Emagisoft.



<PAGE>



     In the short term, to fund  operations  through the balance of fiscal 2001,
the Company will seek additional  funds from strategic  alliances with potential
clients,  its shareholders,  from additional third party financing or seek third
party  debt  or  equity  financing  other  than  those  planned  by the  current
agreements. Additionally, the Company anticipates that revenues will continue to
be generated from the sale of SutureMate(R)  and that such revenues will help to
fund  operations.  Provided  that  additional  funding is  secured,  the Company
believes that it can meet its capital  needs  through year end.  There can be no
assurance that the Company will be successful in these efforts.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital  expenditures  (including the amount and nature thereof),  demand
for the Company's  products and services,  expansion and growth of the Company's
business and operations, and other such matters are forward-looking  statements.
These  statements  are based on certain  assumptions  and  analyses  made by the
Company in light of its  experience  and its  perception of  historical  trends,
current conditions and expected future  developments as well as other factors it
believes are appropriate in the circumstances.  However,  whether actual results
or developments will conform with the Company's  expectations and predictions is
subject  to a number of risks and  uncertainties,  general  economic  market and
business  conditions;  the business  opportunities (or lack thereof) that may be
presented  to and pursued by the  Company;  changes in laws or  regulation;  and
other   factors,   most  of  which  are  beyond  the  control  of  the  Company.
Consequently, all of the forward-looking statements made in this Form 10-QSB are
qualified by these cautionary  statements and there can be no assurance that the
actual results or  developments  anticipated by the Company will be realized or,
even if substantially  realized, that they will have the expected consequence to
or effects on the Company or its business or operations.

PART II

Item 1.  Legal Proceedings.

     On March 13, 2001,  the Company was served with a Summons and  Complaint by
IBM in an action  entitled  International  Business  Machines v. Surgical Safety
Products  Inc.  (The  "Action").  The Action was brought in the Circuit Court in
Sarasota  Florida.  In the Action,  IBM has  brought  four (4) causes of action,
namely,  breach  of  contract,  implied  contract,  account  stated  and  unjust
enrichment.  Each cause of action relates to the contract  between  Surgical and
IBM  relative to the delivery of services  and  equipment.  Surgical had entered
into the arrangement  with IBM to meet its  commitments to US Surgical.  When US
Surgical failed to perform as expected, Surgical sought


<PAGE>



termination of the arrangement with IBM.  Effective July 14, 2000, this contract
was  terminated.  Surgical has been working with IBM in an effort to settle this
matter.  Counsel for Surgical is reviewing  the Complaint  and  determining  the
defenses  Surgical will interpose.  In addition  consideration is being given to
whether or not it should bring a third party action against US Surgical.  IBM is
seeking  payment of in excess of $600,000  for invoices  principally  related to
software  and labor  associated  with  implementing  the US Surgical  Agreement.
Should IBM prevail in this Action,  it would have a material adverse effect upon
Surgical's financial condition. The Company brought a motion to dismiss three of
the causes of action  that was denied and now is  required  to file a defense by
June 5, 2001.The Company intends to file a defense.  The Company believes it has
an absolute defense to the breach of contract claim since the agreement provided
that the Company  could  terminate  and provided the payments  required for such
termination.  Further the agreement  required that the Company  approve all work
prior to  performance  and the work for which it was invoiced was not  approved.
The implied  contract  and unjust  enrichment  claims can only go forward if the
there is no valid contract  since they are  alternative  pleadings.  The Company
believes that it has just and meritorious defenses to this action.

     The Company knows of no other legal  proceedings  to which it is a party or
to which any of its property is the subject,  which are pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.

Item 2. Changes in Securities and Use of Proceeds

     There were no changes in the  Company's  securities  in the  quarter  ended
March 31, 2001.

Item 3.  Defaults in Senior Securities

           None

Item 4. Submission of Matters to a Vote of Security Holders.

     No matters were  submitted  to the  Security  Holders for a vote during the
quarter ended March 31, 2001.

Item 5. Other Information

           None




<PAGE>


Item 6.  Exhibits and Reports on Form 8-K

(a)  The exhibits  required to be filed herewith by Item 601 of Regulation  S-B,
     as described in the following index of exhibits, are incorporated herein by
     reference, as follows:

<TABLE>
<CAPTION>
Item No.             Description
-----------------------------------

<S>       <C>        <C>
3.(I).1              Articles of Incorporation of Surgical Safety Products, Inc., a Florida corporation filed
                     May 15, 1992 [1]

3.(I).2              Articles of Amendment filed December 9, 1992 [1]

3.(I).3              Articles of Amendment filed July 19, 1994 [1]

3.(I).4              Articles of Amendment filed October 11, 1994 [1]

3.(I).5              Articles of Incorporation of Sheffeld Acres, Inc., a New York Corporation filed May
                     7, 1993 [1]

3.(I).6              Articles of Merger filed in the State of Florida October 12, 1994 [1]

3.(I).7              Certificate of Merger filed in the State of New York February 8, 1995 [1]

3.(I).8              Certificate to Do Business in the State of Florida filed April 11, 1995 [1]

3.(I).9              Certificate of Amendment filed May 1, 1998 [1]

3.(I).10             Certificate of Amendment filed February 28, 2000 [7]

3.(II).1             Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety Products, Inc. [1]

3.(II).2             Amended Bylaws of Surgical Safety Products, Inc. [2]

10.1                 Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE dated December 8, 1997 [1]

10.2                 Prepaid Capital Lease Agreement with Community Health Corporation relative to
                     Sarasota Medical Hospital OASiS Installation dated January 30, 1998 [1]

10.3                 Letter of Intent with United States Surgical Corporation dated February 12, 1998 [1]

10.4                 Form of Rockford Industries, Inc. Rental Agreement and Equipment Schedule to
                     Master Lease Agreement [1]

10.5                 Ad-Vantagenet Letter of Intent dated June 19, 1998 [1]

10.6                 Distribution Agreement with Morrison International Inc. dated September 30, 1996 [1]
</TABLE>



<PAGE>



<TABLE>
<S>       <C>        <C>
10.7                 Distribution Agreement with Hospital News dated August 1, 1997 [1]

10.8                 Clinical Products Testing Agreement with Sarasota Memorial Hospital dated January
                     30, 1998 [1]

10.9                 Real Estate Lease for Executive Offices effective June 1, 1998 [1]

10.10                Employment Agreement with Donald K. Lawrence dated April 1, 1997 [1]

10.11                Employment Agreement with G. Michael Swor dated June 15, 1998 [1]

10.12                Employment Agreement with Frank M. Clark dated June 15, 1998 [1]

10.13                Agreement for Consulting Services with Stockstowatch.com Inc. dated March 30,
                     1988 [1]

10.14                Form of Employee Option Agreement dated July 1994 [1]

10.15                Form of Employee Option Agreement dated 1998 [1]

10.16                Form of Consultants Option Agreement dated July 1994 [1]

10.17                Form of Consultants Option Agreement dated 1998 [1]

10.18                Confidential Private Offering Memorandum dated May 30, 1995 [1]

10.19                Supplement to Private Offering Memorandum dated October 30, 1995 [1]

10.20                Stock Option Agreement with Bay Breeze Enterprises LLC dated April 9, 1998 [1]

10.21                Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
                     Bank dated May 2, 1997 [1]

10.22                Agreement between the Company and T. T. Communications, Inc. dated October 15,
                     1998 [2]

10.23                Agreement between the Company and U.S. Surgical Corporation dated October 28,
                     1998. [2]
</TABLE>


<PAGE>



<TABLE>
<S>       <C>        <C>
10.24                Collaborative Agreement between the Company and Dr. William B. Saye dated
                     November 16, 1998. [2]

10.25                Kiosk Information System, Inc. Purchase Order dated November 3, 1998 [2]

10.26                Surgical Safety Products 1999 Stock Option Plan adopted January 1999 [2]

10.27                Form of the Employee Option Agreement under the Surgical Safety Products 1999
                     Stock Option Plan dated January 1999 [2]

10.28                Form of the Director, Consultant and Advisor Option Agreement under the Surgical
                     Safety Products 1999 Stock Option Plan dated January 1999 [2]

10.29                Verio, Inc. Access Service Agreement dated February 16, 1999. [2]

10.30                Form of Investor Subscription Documents and Agreements relative to the April 1999
                     Self Directed Private Placement Offering under Rule 506 of Regulation D. [3]

10.31                Form of the Warrant issued pursuant to the April 1999 Self Directed Private Placement
                     Offering under Rule 506 of Regulation D. [3]

10.32                Consulting Agreement dated April 1999 with Koritz Group, LLC. [3]

10.33                Agreement dated April 1999 with KJS Investment Corporation. [4]

10.34                Agreement dated May 1999 with Ten Peaks Capital Corp. [4]

10.35                Private Partner Network Agreement dated July 30, 1999 with US Surgical [5]

10.36                Staff/Client Leasing Agreement dated October 16, 1999, as amended September 15,
                     1999 [5]

10.37                Agreement dated July 15, 1999 with Triton Capital Inc.[6]

10.38                Effective December 30, 1999, Loan Agreement, Note, Security Agreement, Lender's
                     Warrant, Agent's Warrant, Registration Rights Agreement and Escrow Agreement
                     relative to the December 1999 transaction with Thomson Kernaghan & Co., Inc.  and
                     Amendment thereto. [7]
</TABLE>


<PAGE>



<TABLE>
<S>       <C>        <C>
10.39                Effective January 3, 2000 IBM Customer Agreement and Statement of Work. [7]

10.40                Investment Banking Services Agreement dated February 2, 2000 with Dunwoody
                     Brokerage Services Inc. [8]

10.41                Consulting Agreement dated February 15, 2000 with Global Development Advisors
                     Inc. [8]

10.42                Surgical Safety Products 2000 Stock Option and Award Plan [8]

10.43                Agreement with Steel Beach Productions dated February 29, 2000 [9].

10.44                Agreement with Horizon Marketing Group dated May 16, 2000 [10]

10.45                Agreement with EPIX dated May 25, 2000 [10]

10.46                Amendment to the Company's 2000 Stock Option and Awards Plan dated June 6, 2000
                     [10]

10.47                Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
                     Bank dated June 7, 2000 [10]

10.48                Agreement with AORN effective July 1, 2000 [10]

10.49                Agreement with Carver Cross dated July 6, 2000 [10]

10.50                Agreement with U.S. Surgical effective June 28, 2000 [11]

10.51                Agreement with Imagyn dated September 18, 2000 [12]

10.52                Agreement with Haemacure dated September 19, 2000 [12]

10.53                Agreement with Storz dated September 29, 2000 [12]

10.54                Agreement with Quantum dated October 6, 2000 [12]

10.55                Agreement with Stryker dated October 9, 2000 [12]
</TABLE>


<PAGE>



<TABLE>
<S>       <C>        <C>
10.56                Property Lease dated October 13, 2000 [12]

10.57                Agreement with GDA dated October 25, 2000 [12]

10.58     *          Loan Cancellation and Settlement Agreement with Thomson Kernaghan & Co.  Ltd.
                     effective February 7, 2001

10.59     *          Term Sheet for merger with Emagicsoft Technologies Inc.  dated February, 2001

10.60     *          Selective HR Solutions Agreement dated March 2001.

10.61     *          DeRoyal Industries, Inc.  Agreement dated 2001

13.1                 Definitive Proxy Statement filed February 28, 2000 [8]
----------------
</TABLE>

[1]  Previously filed with the Company's Form 10SB

[2]  Previously filed with the Company's Amendment No. 1 to the Form 10SB

[3]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     30, 1999

[4]  Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 1999

[5]  Previously filed with the Company's Amendment No. 2 to the Form 10SB

[6]  Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 1999

[7]  Previously filed with the Company's Form S-3 on March 2, 2000.

[8]  Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 1999.

[9]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     31, 2000.

[10] Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 2000.

[11] Previously  filed with the Company's  Amendment 3 to the Form 10QSB for the
     Quarter ended June 30, 2000.



<PAGE>


[12] Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 2000.

[13] Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 2000.


     (b) No Reports on Form 8-K were filed  during the  quarter  ended March 31,
2001.




<PAGE>




                                   SIGNATURES

     In accordance  with Section 12 of the Securities  Exchange Act of 1934, the
registrant caused this Registration  Statement to be signed on its behalf by the
undersigned,   thereunto  duly  authorized.   Surgical  Safety  Products,   Inc.
(Registrant)

Date: May 24, 2001       By:/s/Dr. G. Michael Swor
                         ---------------------------------------
                         Dr.  G.  Michael Swor, Chief
                         Financial Officer




<PAGE>